Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Thyroxine for Avolition in Schizophrenia
NCT07011953Phase 1Not yet recruiting
- Sponsor
- Peking University
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of levothyroxine sodium in schizophrenia (2 arms), sponsored by Peking University. Primary endpoint: Negative Symptom Assessment Motivation Subscale at 8 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
levothyroxine sodium
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07011953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011953.